This article was subjected to a comprehensive fact-checking process. Our professional fact-checkers verify article information against primary sources, reputable publishers, and experts in the field.

Credit: Dalin Ou via Getty Images. US biotech Merida Biosciences has launched with $121m in Series A financing to develop therapeutics targeting disease-causing antibodies in autoimmune diseases and ...

Global pharmaceutical stocks plunged on the news Wednesday, with U.K.-based AstraZeneca dropping 5% and Swiss drugmaker Novartis losing 3% in early trading on U.S. exchanges. Top U.S. drugmakers, ...

Merida Biosciences, a startup formed by venture capital firm Third Rock Ventures, emerged from stealth Tuesday, revealing $121 million in financing and a lead program for a common autoimmune ...

Merida Therapeutics was seeded by Third Rock back in 2022, when the biotech’s co-founder and chief scientific officer Dario Gutierrez, Ph.D., was entrepreneur-in-residence at the VC firm.

A scrap­py team of drug de­vel­op­ers has come to­geth­er to cre­ate new med­i­cines for pa­tients with au­toim­mune dis­eases and al­ler­gies. They’re go­ing af­ter the ...

April 08, 2025--(BUSINESS WIRE)--Merida Biosciences, a biotechnology company pioneering a new class of precision therapeutics designed to selectively and durably eliminate the pathogenic antibody ...

Series A financing co-led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures Merida Biosciences, a biotechnology company pioneering a new class of precision therapeutics designed ...

A new biotech, Merida Biosciences, has launched with $121 million in the bank to advance a new class of precision treatments for autoimmune and allergic diseases. Merida’s therapies are “antibody-like ...

Series A financing co-led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merida Biosciences, a biotechnology company pioneering a new class of ...